According to our latest study on “Monoclonal Antibodies Market Size and Forecast to 2028 – COVID-19 Impact and Global Analysis – by Source, Production Method, Indication, Application, End-User,” the market is projected to reach US$ 243.05 billion by 2028 from US$ 111.01 billion in 2021; it is expected to grow at a CAGR of 11.8% from 2021 to 2028. The report highlights the key factors driving the market growth and prominent players with their developments in the market.

Get Your Free Sample Copy Today | Click Here:

COVID-19 has a positive impact on the adoption and growth of global monoclonal antibodies market. For example, the NCBI report states that, the Food and Drug Administration (FDA) announced emergency use authorization (EUA) for three monoclonal antibodies intended for COVID-19 patients with allocation of nearly 1 billion antibody treatments. Also, monoclonal antibodies remain the only approved outpatient therapies intended for COVID-19 patients. Also, various regulatory agencies have favorable policies related to monoclonal antibodies effective for COVID-19 situations. For example, The Crown report states that, in August 2020, the Medicines and Healthcare products Regulatory Agency (MHRA) announced granting approval for the first monoclonal antibody treatment intended for the prevention of COVID-19 in UK. Such aforementioned factors have a positive impact on the market growth during the analysis period from 2021 to 2028.

Based on indication, the monoclonal antibody market is segmented into cancer, autoimmune diseases, infectious diseases, inflammatory diseases, microbial diseases, and others. The cancer segment held the largest share of the market in 2021 and is projected to register the highest CAGR during the forecast period. On the other hand, the autoimmune diseases segment is estimated to register the second-highest CAGR in the market during the forecast period. Cancer metastasis causes a majority of mortalities and morbidities among cancer patients. A traditional cancer therapy focuses on the removal or destruction of tumor cells through surgery, radiation, and rather non-selective types of chemotherapy. Therefore, there is a high demand for antitumor monoclonal antibodies (mABs). For example, the Food and Drug Administration (FDA)has approved several specially engineered humanized or chimeric mABs; these include Alemtuzumab, Bevacizumab, and Cetuximab. Apart from the direct use of mAbs for treating various cancer types, mABs are also used for delivering radioisotopes selectively to cancer cells. For example, mAB-tagged radioisotopes are used for treating patients suffering from non-Hodgkin’s lymphoma and are often used in combination with Rituximab.

Novartis AG; Pfizer Inc.; GlasxoSmithKline plc.; Amgen Inc.; DAICHI SANKYO COMPANY LIMITED; F. HOFFMANN-LA ROCHE LTD.; AstraZeneca; Elli Lilly and Company; Bayer AG; Bristol-Myers Squibb Company are among the leading companies operating in the global monoclonal antibodies market.

The report segments the monoclonal antibodies market as follows:

Based on source, the monoclonal antibodies market is segmented into human, humanized, chimeric, and murine. By production method, the market is segmented into in-vitro and in-vivo. The monoclonal antibodies market, by indication, is further segmented as cancer, autoimmune diseases, infectious diseases, inflammatory diseases, microbial diseases, and others. By application, the market is subsegmented as therapeutic applications, diagnostic applications, and research applications. Furthermore, based on end-user, the market is segmented into hospitals, others, and research institutes.

•          By Geography

Based on geography, the monoclonal antibodies market is primarily segmented into North America, Europe, Asia Pacific, the MEA, and South and Central America. The market in North America is further segmented into the US, Canada, and Mexico. The European monoclonal antibodies market is subsegmented into France, Germany, the UK, Spain, Italy, and the Rest of Europe. The market in Asia Pacific is subsegmented into China, India, Japan, Australia, South Korea, and the Rest of APAC. The monoclonal antibodies market in the MEA is further segmented into Saudi Arabia, the UAE, South Africa, and the Rest of MEA. The market in South and Central America is segmented into Brazil, Argentina, and the Rest of South and Central America.

About US

The Insight Partners is a one stop industry research provider of actionable intelligence. We help our clients in getting solutions to their research requirements through our syndicated and consulting research services. We specialize in industries such as Semiconductor and Electronics, Aerospace and Defense, Automotive and Transportation, Monoclonal Antibodies, Healthcare IT, Manufacturing and Construction, Medical Device, Technology, Media and Telecommunications, Food and Beverages, Consumers and Goods, Chemicals and Materials.

Contact US

Contact Person : Ankit Mathur

Phone : +1-646-491-9876

E-mail : [email protected]

About The Author